APT-1011

DRUG4 trials

Sponsors

Adare Pharmaceuticals, Inc., Ellodi Pharmaceuticals, LP

Conditions

Eosinophilic Esophagitis

Phase 2

Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)

CompletedNCT03191864

Adare Pharmaceuticals, Inc.Eosinophilic Esophagitis

Start: 2017-06-22End: 2019-10-23Updated: 2023-04-26

Phase 3

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

CompletedNCT04281108

Ellodi Pharmaceuticals, LPEosinophilic Esophagitis

Start: 2020-01-30End: 2022-10-24Updated: 2023-06-12

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

CompletedNCT05083312

Ellodi Pharmaceuticals, LPEosinophilic Esophagitis

Start: 2021-09-30End: 2022-09-05Updated: 2023-09-21

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

CompletedNCT05634746

Ellodi Pharmaceuticals, LPEosinophilic Esophagitis

Start: 2022-12-29End: 2024-08-12Updated: 2025-08-13

Related Papers

Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial

Clinical Gastroenterology and Hepatology2022-02-1646 citations